

DAILY EQUITY REPORT

12TH DECEMBER 2018



INDIAN MARKET

INDICES	CLOSE	PREVIOUS
SENSEX	35150.01	35673.25
NIFTY	10549.15	10693.70

ASIAN MARKET

INDICES	CLOSE	PREVIOUS
NIKKEI	21148.02	21678.68
HANG SENG	25771.67	26063.76
KOSPI	2052.97	2075.76

SECTORIAL INDICES

INDICES	CLOSE	CHANGE (%)
CNX 100	10761.75	0.71
S&P CNX 500	8845.15	0.86
CNX MIDCAP	4634.45	1.80
CNX 200	5561.70	0.82
.BANK NIFTY	26163.40	0.23

TOP GAINERS

SCRIPT	CLOSE	CHANGE (%)
YESBANK	179.05	8.09
SUNPHARMA	423.80	6.22
ASIAN PAINT	1322.85	3.82
KOTAK BANK	1239	3.39

TOP LOSERS

SCRIPT	CLOSE	CHANGE (%)
HINDPETRO	219.90	-3.00
IOC	132	-1.75
BHARTIARTL	290.20	-1.61
HDFC BANK	2056.15	-1.56

INDIAN FACE



INDIAN EQUITY BENCHMARK :- At the close of market hours, the Sensex was up 190.29 points or 0.54% at 35150.01, while the Nifty was up 60.70 points or 0.58% at 10549.20. The market breadth was positive as 1623 shares advanced, against a decline of 771 shares, while 139 shares were unchanged. Yes Bank and Sun Pharma were the top gainers, while HDFC Bank, Bharti Airtel, HPCL and IOC lost the most.

GLOBAL FACE



Asian Market - Asian markets finished mixed as of the most recent closing prices. The Shanghai Composite gained 0.37% and the Hang Seng rose 0.07%. The Nikkei 225 lost 0.34%.



U.S. Market – US futures slightly higher as market volatility continues.



European markets - European markets are sharply higher today with shares in France leading the region. The CAC 40 is up 1.56% while Germany's DAX is up 1.49% and London's FTSE 100 is up 1.18%.

MARKET MOVERS UPSIDE

SCRIPT	CLOSE	CHANGE (%)
YES BANK	177.40	7.29
SUN PHARMA	421.80	5.75
PNB	68.60	5.70
SRTRANSFIN	1142.35	4.65

MARKET MOVERS DOWNSIDE

SCRIPT	CLOSE	CHANGE (%)
HPCL	220.35	-2.74
BHARAT FORG	498.30	-1.64
HEROMOTOC OP	2994.00	-1.58
BHARTI ARTL	290.10	-1.43

FII & DII ACTIVITY

INSTITUTION	NET BUY (CR.)	NET SELL (CR.)
FII	4041.44	3925.22
DII	3585.42	3731.22

NSE TOTALS

INDICES	ADVANCE S	DECLINE S
NIFTY	38	12
BANK NIFTY	10	2

NIFTY SPOT

TREND				STRATEGY			
BEARISH				BUY ON DIPS			
PIVOT POINTS							
S3	S2	S1	P	R1	R2	R3	
10015	10249	10399	10483	10633	10717	10951	
SUPPORT			RESISTANCE				
S1-10480			R1-10630				
S2-10390			R2-10710				



TREND				STRATEGY			
BULLISH				BUY ON DIPS			
PIVOT POINTS							
S3	S2	S1	P	R1	R2	R3	
24892	25481	25846	26070	26435	26659	27248	
SUPPORT			RESISTANCE				
S1-26070			R1-26430				
S2-25840			R2-26650				



MARKET TALKS



Cadila arm receives USFDA nod for ulcer treatment injection

Cadila Healthcare arm Liva Pharmaceuticals has received an approval from the US FDA for its supplemental abbreviated new drug application (sANDA) that treats ulcers. Reacting to this, shares of Cadila Healthcare climbed 2% on the BSE in the afternoon session on Tuesday. The company will manufacture Ranitidine Injection USP, 25 mg/mL, 2 mL Single dose vials and 6 mL at Liva Pharms manufacturing facility in Vadodara, the company said in a press note to the exchanges on Tuesday.



Lupin rises 2.5% on getting USFDA approval to market Apixaban tablets

Shares of Lupin were up 2.5% in the morning trade on tuesday as the pharma major announced in an exchange filing on Monday that it has received tentative approval from the USFDA to market Apixaban Tablets, 2.5 mg and 5 mg, a generic version of Bristol-Myers Squibb Company's Eliquis® Tablets, 2.5 mg and 5 mg. Read more. Lupin Limited is a transnational pharmaceutical company based in Mumbai. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.



Yes Bank trades up 5% amid market uncertainty

Shares of Yes Bank were trading up 5% on Tuesday even amid the election anxiety that had gripped the markets. The Nifty Private Bank index, meanwhile, was trading down 0.6% at the same time. Yes Bank's stock has been in a slump after the RBI asked its incumbent MD-CEO Rana Kapoor to quit his post on January 31. Despite the lender's appeal to extend this deadline, the RBI had stuck to its decision.



Strides' JV gets final USFDA approval for gAlbenza

Strides Pharma Science Limited has announced that its 50:50 joint venture with Vivimed named Strides Vivimed Pte. Ltd has received final USFDA approval for Albendazole Tablets (200 mg). Albendazole is an anthelmintic medication used to treat certain infections caused by tapeworm. Albendazole Tablets is a generic version of Albenza Tablets of Amneal Pharmaceuticals, Inc. The company has said that this is the second generic approval by USFDA for Albendazole Tablets. Cipla also has a USFDA approval for gAlbenza.

DISCLAIMER

The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk.

Capitalstars Financial Research Private Ltd., Reserves all Rights.

INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK.

BRANCH OFFICE

Capitalstars Financial Research Private Limited

PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME

NO.54,VIJAYNAGAR INDORE

REGISTERED OFFICE

PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE

Email:-backoffice@capiltalstars.in

Report Is Checked by Investment Advisor: